Performance outcomes of a pharmacist-managed anticoagulation clinic in the rural, resource-constrained setting of Eldoret, Kenya

Journal of Thrombosis and Haemostasis

Volumn 9, Issue 11, 2011, Pages 2215-2220

  Manji, I ^a   Pastakia, S D ^a,b   Do, A N ^b   Ouma, M N ^a   Schellhase, E ^b   Karwa, R ^a,b   Miller, M L ^b   Saina, C ^a   Akwanalo, C ^a  

^a MOI TEACHING AND REFERRAL HOSPITAL   (Kenya)

^b PURDUE UNIVERSITY   (United States)

Author keywords

Anticoagulation; Kenya; Pharmacist; Resource constrained; Thromboembolism; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; ANTIRETROVIRUS AGENT; TUBERCULOSTATIC AGENT; WARFARIN;

ADULT; ANTICOAGULANT THERAPY; ANTICOAGULATION; ANTIVIRAL THERAPY; ARTICLE; BLEEDING; COMPARATIVE STUDY; DRUG INDICATION; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HEART VALVE PROSTHESIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KENYA; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MEDICAL HISTORY; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; PHARMACIST; PHARMACIST MANAGED ANTICOAGULATION; PHARMACOLOGICAL PARAMETERS; PREDICTION; PRIORITY JOURNAL; RHEUMATIC HEART DISEASE; RURAL HEALTH CARE; SECONDARY ANALYSIS; TIME IN THE THERAPEUTIC RANGE; TUBERCULOSIS; TUBERCULOSIS CONTROL; VALVULAR HEART DISEASE; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; DRUG MONITORING; HEALTH RESOURCES; HUMANS; KENYA; PHARMACISTS; RETROSPECTIVE STUDIES; RHEUMATIC HEART DISEASE; RURAL POPULATION; VENOUS THROMBOEMBOLISM; WARFARIN;

EID: 80055116563     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2011.04503.x     Document Type: Article

References (26)

1. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek R. The pharmacology and management of Vitamin K antagonists: the seventh ACCP conference on anticoagulants and thrombolytics. Chest 2004; 126: 204-33.
2. Kaatz S. Determinants and measures of quality in oral anticoagulation therapy. J Thromb Thrombolysis 2008; 25: 61-6.
3. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of Vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 160S-98S.
4. Bungard TJ, Gardner L, Archer SL, Hamilton P, Ritchie B, Tymchak W, Tsuyuki RT. Evaluation of a pharmacist-managed anticoagulation clinic: improving patient care. Open Med 2009; 3: e16-21.
5. Pengo V, Pegoraro C, Cucchin U, Iliceto S. Worldwide management of oral anticoagulant therapy. J Thromb Thrombolysis 2006; 21: 73-7.
6. Dager WE, Gulseth MP. Implementing anticoagulation management by pharmacists in the inpatient setting. Am J Health-Syst Pharm 2007; 64: 1071-9.
7. Poon IO, Lal L, Brown EN, Braun UK. The impact of pharmacist managed oral anticoagulation therapy in older veterans. J Clin Pharm Ther 2007; 32: 21-9.
8. Jackson SL, Peterson GM, Bereznicki LR, Misan GM. Improving the outcomes of anticoagulation in rural Australia: an evaluation of pharmacist-assisted monitoring of warfarin therapy. J Clin Pharm Ther 2005; 30: 345-53.
9. Baker WL, Cios DA, Sander SD, Coleman CI. Meta-analysis to assess quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm 2009; 15: 244-52.
10. Ogendo SW. Pattern of anticoagulation control after heart valve surgery at the Kenyatta National Hospital, Nairobi. East Afr Med J 2000; 77: 354-8.
11. Ogendo SW. Warfarin-related bleeding following open heart surgery in Nairobi. East Afr Med J 2001; 78: 139-43.
12. Schapkaitz E, Jacobson BF, Becker P, Conway G. Thrombo-embolic and bleeding complications in patients with mechanical valve replacements - a prospective observational study. S Afr Med J 2006; 96: 710-3.
13. Essop MR, Nkomo VT. Rheumatic and nonrheumatic valvular heart disease: epidemiology, management, and prevention in Africa. Circulation 2005; 112: 3584-91.
14. Pastakia SD, Fohl AL, Schellhase EM, Manji I, Ringenberg K. Needs assessment analysis for vitamin K antagonist anticoagulation in the resource-constrained setting of Eldoret, Kenya. J Am Pharm Assoc 2010; 50: 723-5.
15. Pastakia SD, Crisp WI, Schellhase EM, Manji I, Ouma MN, Akwanalo C. Implementation of a pharmacist managed anticoagulation clinic in Eldoret, Kenya. Southern Med Review 2010; 3: 20-3.
16. Schulman S, Beyth RJ, Kearon C, Levine MN. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 257S-98S.
17. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 236-9.
18. Lee CR, Thrasher KA. Difficulties in anticoagulation Management during co-administration of warfarin and rifampin. Pharmacotherapy 2001; 21: 1240-6.
19. Liedtke MD, Rathbun RC. Warfarin-Antiretroviral interactions. Ann Pharmacother 2009; 43: 322-8.
20. de Assis MC, Rabelo ER, Avila CW, Polanczyk CA, Rohde LE. Improved oral anticoagulation after a dietary vitamin k-guided strategy: a randomized controlled trial. Circulation 2009; 120: 1115-22.
21. Orech FO, Christensen DL, Larsen T, Friis H, Aagaard-Hansen J, Estambale BA. Mineral content of traditional leafy vegetables from western Kenya. Int J Food Sci Nutr 2007; 58: 595-602.
22. Nutrient Data Products and Services. Accessed on 5 May 2011.
23. Takahashi H, Wilkinson GR, Nutescu EA, Morita T, Ritchie MD, Scordo MG, Pengo V, Barban M, Padrini R, Ieiri I, Otsubo K, Kashima T, Kimura S, Kijima S, Echizen H. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics 2006; 16: 101-10.
24. Kealey C, Chen Z, Christie J, Thorn CF, Whitehead AS, Price M, Samaha FF, Kimmel SE. Warfarin and cytochrome P450 2C9 genotype: possible ethnic variation in warfarin sensitivity. Pharmacogenomics 2007; 8: 217-25.
25. Bussey HI. Transforming oral anticoagulation by combining international normalized ratio (INR) self-testing and online automated management. J Thromb Thrombolysis 2011; 31: 265-74.
26. Bisno A, Butchart EG, Ganguly NK, Ghebrehiwet T, Lue H, Kaplan EL, Kordofani N, Martin D, Millard D, Narula J, Vanuzzo D, Zaher SRA. Rheumatic fever and rheumatic heart disease: report of a WHO Expert Consultation, Geneva, 29 October - 1 November 2001. WHO Technical Report Series 2004; 923: 3-12.